{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:49:10Z","timestamp":1787500150633,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00685654","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T09:45:10Z","timestamp":1101635110000},"page":"455-458","source":"Crossref","is-referenced-by-count":10,"title":["Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice"],"prefix":"10.1007","volume":"34","author":[{"given":"Marlene A.","family":"Bunni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Sirotnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenys M.","family":"Otter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Priest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","first-page":"345","volume":"38","author":"FM Sirotnak","year":"1978","unstructured":"Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer 38: 345","journal-title":"Cancer"},{"key":"CR2","first-page":"4679","volume":"36","author":"FM Sirotnak","year":"1976","unstructured":"Sirotnak FM, Donsbach RC, Moccio DM, Dorick DM (1976) Biochemical and pharmacokinetic effects of leucovorin after highdose methotrexate in a murine leukemia model. Cancer Res 36: 4679","journal-title":"Cancer Res"},{"key":"CR3","first-page":"3493","volume":"50","author":"JA Houghton","year":"1990","unstructured":"Houghton JA, Williams LG, DeGraaf SSN, Cheshire PJ, Rodman JH, Maneval DC, Wainer IW, Jadaud P, Houghton PJ (1990) Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50: 3493","journal-title":"Cancer Res"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4684-5607-3_3","volume":"244","author":"RJ Mullin","year":"1988","unstructured":"Mullin RJ, Keith BR, Duch DS (1988) Distribution and metabolism of calcium leucovorin in normal and tumor tissue. Adv Exp Med Biol 244: 25","journal-title":"Adv Exp Med Biol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/jnci\/83.24.1806","volume":"83","author":"DG Priest","year":"1991","unstructured":"Priest DG, Schmitz JC, Bunni MA, Stuart RK (1991) Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83: 1806","journal-title":"J Natl Cancer Inst"},{"key":"CR6","first-page":"2592","volume":"49","author":"JE Wright","year":"1989","unstructured":"Wright JE, Dreyfuss A, El-Magharbel I, Trites D, Jones SM, Holden SA, Rosowsky A, Frei E III (1989) Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49: 2592","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1172\/JCI112872","volume":"79","author":"J Baram","year":"1987","unstructured":"Baram J, Allegra CJ, Fine RL, Chabner BA (1987) Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 79: 692","journal-title":"J Clin Invest"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/00032719208018521","volume":"25","author":"DG Priest","year":"1992","unstructured":"Priest DG, Bunni MA, Mullin RJ, Duch DS, Galivan J, Rhee MS (1992) A comparison of HPLC and ternary complex-based assays of tissue reduced folates. Anal Lett 25: 219","journal-title":"Anal Lett"},{"key":"CR9","first-page":"4204","volume":"49","author":"DG Priest","year":"1989","unstructured":"Priest DG, Bunni M, Sirotnak M (1989) Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo. Cancer Res 49: 4204","journal-title":"Cancer Res"},{"key":"CR10","first-page":"1488","volume":"45","author":"LL Samuels","year":"1988","unstructured":"Samuels LL, Moccio DM, Sirotnak FM (1988) Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro. Cancer Res 45: 1488","journal-title":"Cancer Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248","journal-title":"Anal Biochem"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0305-7372(83)80032-2","volume":"10","author":"JH Schornagel","year":"1983","unstructured":"Schornagel JH, McVie JG (1983) The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53","journal-title":"Cancer Treat Rev"},{"key":"CR13","doi-asserted-by":"crossref","unstructured":"Schmitz, JC, Grindey GB, Schultz RM, Priest DG (1994) Impact of dietary folic acid on reduced folates in mouse plasma and tissues: relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol (in press)","DOI":"10.1016\/0006-2952(94)90103-1"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685654\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T06:10:32Z","timestamp":1554444632000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00685654"],"URL":"https:\/\/doi.org\/10.1007\/bf00685654","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}